

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7733246

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
IMARA, INC.	11/10/2022
RECEIVING PARTY DATA	
Name:	CARDURION PHARMACEUTICALS, INC.
Street Address:	78 BLANCHARD ROAD, SUITE 200
City:	BURLINGTON
State/Country:	MASSACHUSETTS
Postal Code:	01803
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16615347
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6179372300
Email:	jsteinfield@cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	1299 PENNSYLVANIA AVENUE NW
Address Line 2:	SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	CDPH-011N01US 341287-2382
NAME OF SUBMITTER:	HENG ZHANG
SIGNATURE:	/HENG ZHANG/
DATE SIGNED:	01/10/2023
Total Attachments: 12	
source=Assignment-Imara-Cardurion#page1.tif	
source=Assignment-Imara-Cardurion#page2.tif	
source=Assignment-Imara-Cardurion#page3.tif	
source=Assignment-Imara-Cardurion#page4.tif	
source=Assignment-Imara-Cardurion#page5.tif	

source=Assignment-Imara-Cardurion#page6.tif
source=Assignment-Imara-Cardurion#page7.tif
source=Assignment-Imara-Cardurion#page8.tif
source=Assignment-Imara-Cardurion#page9.tif
source=Assignment-Imara-Cardurion#page10.tif
source=Assignment-Imara-Cardurion#page11.tif
source=Assignment-Imara-Cardurion#page12.tif

PATENT ASSIGNMENT

This Patent Assignment dated as of November 10, 2022 (this "Patent Assignment"), is made by and between Imara Inc., a Delaware corporation ("Assignor"), and Cardurion Pharmaceuticals Inc., a Delaware corporation ("Assignee"). Capitalized terms used but not otherwise defined herein, shall have the meanings given to such terms in the Purchase Agreement (as defined below).

WHEREAS, Assignor and Assignee are parties to an Asset Purchase Agreement dated as of September 6, 2022, by and between Assignor and Assignee (the "Purchase Agreement") pursuant to which, among other things, Assignor has agreed to transfer to Assignee all of Assignor's rights, title and interest in and to the Assigned Patent Rights; and

WHEREAS, Assignor is the sole and exclusive owner, by assignment, of the patent applications listed on attached Schedule A and own the rights for the inventions and the related patents and patent applications listed on Schedule A, which are filed in the United States Patent and Trademark Office ("USPTO") and other patent offices, together with all non-provisional, divisional, continuation, reissue, reexamination and other patent applications claiming priority thereto (the "Patent Applications") and any and all patents and like rights of exclusion (including extensions thereof) of any country which may be granted on said Patent Applications (the "Patents");

NOW THEREFORE, for good and valuable consideration in connection with the sale and purchase of assets pursuant to the Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby agree as follows:

1. Assignment. Assignor hereby irrevocably conveys, sells, assigns, transfers, and sets over to Assignee and its successors and assigns, and Assignee hereby accepts for the territory of the United States of America and throughout the world all of Assignor's entire rights, title, and interest (including the right to sue and recover for past infringement) in and to Patents and Patent Applications as well as all of the rights incident to such ownership provided by the law of any applicable jurisdiction, by international treaty or convention or otherwise throughout the world to be held and enjoyed by the said Assignee for its own use and behalf and for its successors and assigns any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to the foregoing.

2. Recordation. This Patent Assignment may be recorded with any applicable national, federal and state government authorities including, but not limited to, the USPTO. Assignor authorizes the Commissioner of Patents of the USPTO and any other official throughout the world charged with the registration and recordation of ownership in the Patents and Patent Applications to record Assignee as the assignees and owner of the Patents and Patent Applications and to issue all Patents and Patent Applications on Schedule A to Assignee.

3. Further Assurances. Assignor shall execute any and all documents, take all lawful oaths and take all other further actions as reasonably requested by Assignee to

record this Patent Assignment with the USPTO and to transfer title of the Patents and the Patent Applications to Assignee, including, but not limited to, assignments, transfers and related powers of attorney. Assignor agrees to ratify and hereby ratifies any acts of Assignee in applying for a patent in respect of any Patent or Patent Application in Assignee's own name in any jurisdiction where such procedure is proper and agrees to execute or have executed any documents or assignments where it is necessary that they be executed by the inventor(s) and Assignor further agrees to execute assignments of any patent applications.

4. Terms of Purchase Agreement. Each of Assignor and Assignee acknowledges and agrees that neither the representations and warranties nor the rights and remedies of any Party under the Purchase Agreement shall be deemed to be enhanced, modified or altered in any way by this Patent Assignment, nor shall any provision hereof be deemed to be a representation or warranty of Assignor for the purpose of Section 9.4 of the Purchase Agreement or a representation or warranty of Assignee for the purpose of Section 9.5 of the Purchase Agreement. The Purchase Agreement shall govern in the case of any conflict, ambiguity or inconsistency between this Patent Assignment and the Purchase Agreement.

5. Counterparts. This Patent Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed one and the same agreement. A signed copy of this Patent Assignment delivered by facsimile, e-mail, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Patent Assignment.

6. Successors and Assigns. This Patent Assignment shall be binding upon and shall inure to the benefit of the Assignee and its successors and assigns.


7. Governing Law. This Patent Assignment and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based upon, arising out of, or relating to this Patent Assignment and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the Commonwealth of Massachusetts, without giving effect to its internal rules governing the conflict of laws.

[Signature Pages to follow]

IN WITNESS WHEREOF, Assignors have duly executed and delivered this Patent Assignment as of the date first written above.

ASSIGNOR

IMARA INC.


By: 

Name: Rahul Ballal
Title: Chief Executive Officer

Address for Notices: 116 Huntington Avenue, 6th
Floor, Boston MA 02116


STATE OF Massachusetts
COUNTY OF Suffolk ss.

BEFORE ME personally appeared the said Rahul Ballal, Chief Executive Officer of Assignor and acknowledged the foregoing to be the act and deed of said entity, this 9th day of November, 2022.



Notary Public in and for
the Commonwealth of _____

My commission expires:



AGREED TO AND ACCEPTED:

ASSIGNEE

CARDURION PHARMACEUTICALS, INC.

By: _____

Name:
Title:

IN WITNESS WHEREOF, Assignors have duly executed and delivered this Patent Assignment as of the date first written above.

ASSIGNOR

IMARA INC.

By: _____

Name:

Title:

Address for Notices:

STATE OF _____

COUNTY OF _____ ss.

BEFORE ME personally appeared the said Rahul Ballal, Chief Executive Officer of Assignor and acknowledged the foregoing to be the act and deed of said entity, this ____ day of November, 2022.


Notary Public in and for
the Commonwealth of _____

My commission expires:

AGREED TO AND ACCEPTED:

ASSIGNEE

CARDURION PHARMACEUTICALS, INC.

By:  _____

Name: Peter Lawrence

Title: Chief Executive Officer

SCHEDULE A

Assigned Patent Applications

Country	Title	Appl. No. / Patent No.	Filing Date	Status
Taiwan	PDE9 INHIBITORS FOR TREATING THALASSEMIA	109115096	06-May-2020	Pending
China	PDE9 INHIBITORS FOR TREATING THALASSEMIA	202080049907.0	06-May-2020	Pending
Israel	PDE9 INHIBITORS FOR TREATING THALASSEMIA	287865	06-May-2020	Pending
Australia	PDE9 INHIBITORS FOR TREATING THALASSEMIA	2020267475	06-May-2020	Pending
South Africa	PDE9 INHIBITORS FOR TREATING THALASSEMIA	2021/08851	06-May-2020	Pending
ARIPO	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	AP/P/2019/011257	30-Jun-2017	Pending
Nigeria	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	NG/PT/C/2019/3402	30-Jun-2017	Granted
Europe	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	17740535.4	30-Jun-2017	Pending
Australia	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	2017292650	30-Jun-2017	Pending
Brazil	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	BR112019000005 4	30-Jun-2017	Pending
Israel	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	264048	30-Jun-2017	Pending
Mexico	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	MX/a/2018/016127	30-Jun-2017	Pending

Country	Title	Appl. No. / Patent No.	Filing Date	Status
South Africa	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	2019/00055	30-Jun-2017	Pending
Algeria	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	180594	30-Jun-2017	Pending
Egypt	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	PCT 8/2019	30-Jun-2017	Pending
Morocco	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	44025	30-Jun-2017	Granted
Tunisia	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	TN2018/0383	30-Jun-2017	Pending
UAE	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	P6000023/2019	30-Jun-2017	Pending
Bahrain	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	BP3/2019	30-Jun-2017	Pending
Hong Kong	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	19130289.2	30-Jun-2017	Pending
US	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	17/067,588	09-Oct-2020	Pending
India	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	202118041539	30-Jun-2017	Pending
China	PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES	202210219655.2	30-Jun-2017	Pending
Taiwan	METHODS OF MAKING AND USING PDE9 INHIBITORS	107117910	25-May-2018	Pending
China	METHODS OF MAKING AND USING PDE9 INHIBITORS	201880049927.0	25-May-2018	Pending

Country	Title	Appl. No. / Patent No.	Filing Date	Status
Brazil	METHODS OF MAKING AND USING PDE9 INHIBITORS	1120190248773	25-May-2018	Pending
US	METHODS OF MAKING AND USING PDE9 INHIBITORS	11,370,795	20-Nov-2019	Issued
Canada	METHODS OF MAKING AND USING PDE9 INHIBITORS	3,064,004	25-May-2018	Pending
Korea	METHODS OF MAKING AND USING PDE9 INHIBITORS	10-2019-7038404	25-May-2018	Pending
Japan	METHODS OF MAKING AND USING PDE9 INHIBITORS	2019-565330	25-Nov-2018	Pending
Thailand	METHODS OF MAKING AND USING PDE9 INHIBITORS	1901007437	25-May-2018	Pending
Israel	METHODS OF MAKING AND USING PDE9 INHIBITORS	270792	25-May-2018	Pending
Eurasia	METHODS OF MAKING AND USING PDE9 INHIBITORS	201992721	25-May-2018	Pending
Mexico	METHODS OF MAKING AND USING PDE9 INHIBITORS	MX/a/2019/014049	25-May-2018	Pending
India	METHODS OF MAKING AND USING PDE9 INHIBITORS	201917049959	25-May-2018	Pending
Europe	METHODS OF MAKING AND USING PDE9 INHIBITORS	18805780.6	25-May-2018	Pending
Hong Kong	METHODS OF MAKING AND USING PDE9 INHIBITORS	62020020156.9	25-May-2018	Pending
US	METHODS OF MAKING AND USING PDE9 INHIBITORS	17/723,669	19-Apr-2022	Pending
US	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	17/186,442	26-Feb-2021	Pending
Brazil	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	1120210036865	29-Aug-2019	Pending
Canada	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	3,110,680	29-Aug-2019	Pending

Country	Title	Appl. No. / Patent No.	Filing Date	Status
China	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	201980071992.8	29-Aug-2019	Pending
Europe	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	19853434.9	29-Aug-2019	Pending
Eurasia	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	202190460	29-Aug-2019	Pending
Korea	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	10-2021-7009591	29-Aug-2019	Pending
Australia	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	2019328299	29-Aug-2019	Pending
South Africa	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	2021/01352	29-Aug-2019	Pending
Japan	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	2021-510225	29-Aug-2019	Pending
Thailand	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	2101001126	29-Aug-2019	Pending
Australia	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	2019275075	23-May-2019	Pending
Algeria	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	200621	23-May-2019	Pending
ARIPO	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	AP/P/2020/012803	23-May-2019	Pending
Bahrain	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-	216/2020	23-May-2019	Pending

Country	Title	Appl. No. / Patent No.	Filing Date	Status
	3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE			
Brazil	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	1120200240192	23-May-2019	Pending
Canada	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	3,100,988	23-May-2019	Pending
China	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	201980049524.0	23-May-2019	Pending
Europe	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	19807965.9	23-May-2019	Pending
Egypt	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	PCT 1824/2020	23-May-2019	Pending
Israel	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	278875	23-May-2019	Pending
Mexico	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-	MX/a/2020/012636	23-May-2019	Pending

Country	Title	Appl. No. / Patent No.	Filing Date	Status
	3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE			
South Africa	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	2020/07224	23-May-2019	Pending
UAE	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	P6001640/2020	23-May-2019	Pending
Thailand	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	2001006731	23-May-2019	Pending
Japan	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	2020-564326	23-May-2019	Pending
Korea	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	10-2020-7037068	23-May-2019	Pending
Eurasia	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	202092762	23-May-2019	Pending
US	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-	17/110,000	02-Dec-2020	Pending

Country	Title	Appl. No. / Patent No.	Filing Date	Status
	3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE			
Nigeria	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	NG/PT/C/2020/5054	23-May-2019	Pending
Hong Kong	MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE	62021036265.8	23-May-2019	Pending
China	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	202080041606.3	03-Apr-2020	Pending
Canada	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	3,136,128	03-Apr-2020	Pending
Brazil	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	1120210198768	03-Apr-2020	Pending
Europe	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	20783704.8	03-Apr-2020	Pending
Israel	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	286976	03-Apr-2020	Pending
Japan	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	TBD	03-Apr-2020	Pending
South Africa	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	2021/07544	03-Apr-2020	Pending
PCT	METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE	PCT/US2021/045765	12-Aug-2021	Pending
WO	PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE	PCT/US2021/056696	26-Oct-2021	Pending
US	IMPROVED PDE9 INHIBITORS FOR TREATING THALASSEMIA	63/279,583	15-Nov-2021	Pending

Country	Title	Appl. No. / Patent No.	Filing Date	Status
US	METHODS AND COMPOSITIONS FOR TREATING HEART DISEASE	63/321,315	18-Mar-2022	Pending
Egypt	PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE	1229/2014	25-Jan-2013	Abandoned
US	PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE	17/493,677	04-Oct-2021	Abandoned
US	PDE9 INHIBITORS FOR TREATING THALASSEMIA	17/514,337	29-Oct-2021	Abandoned
Brazil	PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE	BR 11 2014 018199 3	25-Jan-2013	Abandoned